VH 4004280
Alternative Names: VH 4004280A; VH-280; VH-4004280Latest Information Update: 03 Oct 2024
At a glance
- Originator ViiV Healthcare
- Class Antiretrovirals
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 24 Jun 2024 ViiV Healthcare completes the phase II CINNAMON trial in HIV-1 infections (Treatment-naive) in USA, Argentina, Canada, France, Germany, Italy, Mexico, Spain and UK(PO) (NCT06039579) (EudraCT2023-505350-18-00)
- 03 Jun 2024 ViiV Healthcare completes phase I clinical trial for HIV-1 infections in United Kingdom (NCT06168318)
- 18 Dec 2023 Phase I clinical trial for HIV-1 infections in United Kingdom (PO) (NCT06168318)